-
Grant of Share Options
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of unapproved share options over ordinary shares of 1 penny each to directors as follows. Lisa Baderoon 3,000,000 share options (exercise price: 2.24p) Laurence Reilly 2,000,000 share options (exercise price: 2.24p) Share Option Period: All Share Options are valid for 10…
-
New intellectual property strategy initiated to significantly enhance patent life and commercial value for P140 technology platform
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that it has initiated a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform. P140 is ImmuPharma’s technology platform for its portfolio in autoimmune diseases. This comprises the lead indication…
-
Incanthera Provides Commercial Update and Revenue Forecasts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc (“Incanthera”), the dermatology and oncology specialist, in which ImmuPharma currently holds a 10.8% shareholding. Within the announcement, Incanthera announces an update on its commercial skincare deal, announced in December 2023, with…
-
Grant of Share Options
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows. The Remuneration Committee (comprising the Non-Executive Directors) has determined that the following unapproved Share Options have been awarded to the Executive Directors with vesting conditions which reflect the corporate objective of restoring and enhancing shareholder value as…
-
IMMUPHARMA AT BIO-EUROPE SPRING 2024. 18-20 March 2024 | Barcelona
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Europe Spring. The event will be held between 18-20 March 2024, in Barcelona. BIO-Europe Spring is the premier springtime partnering event, designed to provide biotechnology companies with the opportunity to present to…
-
Financial, Business and Portfolio Development Update
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce a positive and comprehensive financial, business and portfolio development update. This follows on from our announcement on 19 December 2023, where we provided a detailed update on our late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus…
-
Proactive
Proactive – ImmuPharma discusses financial stability and promising drug developments 6 March 2024 ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments – 6 March 2024
-
TR1 – Major Holding by Lanstead (Date: 28 December 2023)
To view the form of notification click here
-
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce key updates on its late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus (“SLE/Lupus”). Highlights Simbec-Orion has been appointed as the Contract Research Organisation (“CRO”), for the P140 (Lupuzor™) Phase 3 study in SLE, following extensive due-diligence…
